Edison Investment Research - High Peak Royalties (HPR) Termination: Termination of coverage

Report

Edison Investment Research

Termination: Termination of coverage

Edison Investment Research is terminating coverage on High Peak Royalties (HPR). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

02/06/2016 1 EN

Underlying

High Peak Royalties

High Peak Royalties Ltd. High Peak Royalties Limited is engaged in acquisition of royalty and exploration interests in oil and gas assets predominately in Australia and the United States. The Company has royalties on approximately 23 oil and gas projects, including two royalty areas that are in production, located in Australia and the United States. Its portfolio of royalty interests includes PL 171 and ATP 574P; ATP 299P, including the petroleum leases PL29, PL38, PL39, PL52, PL57, PL95, PL169, PL170, PL293, PL294, PL295 and PL298; Pet Gas Field (PL101); Surprise Oil Field (PL6); Longtom Gas Field (VIC/L29 and VIC/P54); WA-314P; WA-315P; EP115NM; PEL512; WA-482-P; EP156, and East Texas, Permian and Texas Gulf Coast Basins in the United States. Its royalty portfolio has access to projects in main oil and gas basins in Australia. Its portfolio spans producing royalties, potential development royalties and exploration royalties.

See profile

AU000000HPR0 Australian Securities Exchange Australia

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

Independent Investment Research

Monthly LMI Update Independent Investment Research

Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked. This compares to the total dividends of 5 cents per share in FY20. The Board has confirmed that, in...

August 6, 2021 August 6, 2021 10 EN

Moody's Investors Service

Moody's downgrades HighPoint's PDR to D-PD on bankruptcy filing

Rating Action: Moody's downgrades HighPoint's PDR to D-PD on bankruptcy filing. Global Credit Research- 15 Mar 2021. New York, March 15, 2021-- Moody's Investors Service, downgraded HighPoint Operating Corporation's Probability of Default Rating to D-PD from C-PD.

EUR 167.87

March 15, 2021 March 15, 2021 5 EN

Moody's Investors Service

HighPoint Operating Corporation: Update following downgrade of bonds to C

Our view of HighPoint reflecting high risk of default, either as a result of our deeming the company's planned bond exchange a distressed exchange or a Chapter 11 filing

EUR 233.15

November 12, 2020 November 12, 2020 8 EN

AGBA - A transformational deal

On 18 April, AGBA announced a surprise deal to acquire 100% of Triller Corp, a global AI-driven social video platform, in an all-stock transaction. Triller is privately-owned but has been independently valued at US$3.2bn. AGBA’s management is using a US$4bn valuation for the combined entity, in which AGBA shareholders will own 20% and Triller shareholders 80%. Triller recorded FY23 revenues of US$45m on 450m user accounts and 2.2m creators but is loss-making. In FY23, AGBA reported revenues of US$54m and 400,000+ clients. The combined group expects synergies from expanding and marketing to Tri...

8h / 23m 8h / 23m 1 EN

Sean Conroy

Sean Conroy

Biodexa Pharmaceuticals - In a period of transition

FY23 was a transitional year for Biodexa, following the restructuring announced in March 2023 into a therapeutic company from a drug delivery specialist, and the implementation of cost-saving initiatives in light of the macroeconomic environment. The pipeline expansion primarily de-risks the business, partially fulfilled with the acquisition of lyn kinase activator tolimidone, for type 1 diabetes (T1D), in late 2023. Management estimates gross cash of £5.97m at end-FY23 to provide a runway into Q424, past the planned Phase IIa trial initiation for tolimidone. The next catalyst will likely be t...

12h / 32m 12h / 32m 1 EN

Toby Thorrington

Toby Thorrington

Norcros - Sale of Johnson Tiles UK agreed

Norcros’s disposal of Johnson Tiles is the latest strategic activity taken by management to better allocate capital to fit with priorities. Last year it closed its UK adhesives operation. Norcros has a compelling investment case, where its new product development initiatives, market positioning and self-help initiatives allow it to take market share in both the UK and South Africa. Its rating is low at 6.0x FY24e P/E, which is attractive, especially when compared to its yield of 5.4% on its well-covered dividend. We retain our estimates and value the shares at 246p, implying c 30% upside.

April 25, 2024 April 25, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN